Aortic & peripheral vascular disease
Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data
Authors' conclusion
LLDs, particularly statins and PCSK9i, significantly protect against aortic diseases, providing a scientific basis for preventing and treating aortic diseases.
Study context
- Population
- UK Biobank participants
- Participants
- 500,000 UK Biobank participants
- Exposure
- Effects of statins, PCSK9 inhibitors (PCSK9i), β-blockers, and calcium channel blockers on the risks of thoracic aortic aneurysm, abdominal aortic aneurysm, and aortic dissection (AD) using genetic variants as proxies
- Outcome
- Aortic aneurysms and AD
Methodological detailsreal-world pharmacovigilance data from the FAERS database
- Real-world pharmacovigilance data from the FAERS database
Main finding
As reported in the abstract
- PCSK9i and statins significantly reduced the risks of aortic aneurysms and AD, respectively
Observational data: associations, not effects.
Further findings
Mediation through metabolites
- The two lipid-lowering drugs (LLDs) reduced the risk of aortic diseases through certain metabolites
Aortic diseases in pharmacovigilance reports (FAERS)
- Low incidence of aortic diseases with PCSK9i and statin treatment
Original publication
Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data. Eur Heart J Cardiovasc Pharmacother. Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →